PSNL personalis.com: שווי החברה בספרים

Personalis, Inc. (PSNL) generates revenue based on cutting-edge genomic research, including tumor diagnostics and analytics for pharmaceutical behemoths. Growth is driven by the implementation of high-sensitivity liquid biopsy tests in oncology centers, and the current price chart on GURU.Markets shows a value of 0.23. The business scales easily thanks to DNA automated sequencing software, which allows for the processing of massive datasets without expanding laboratory staff.

Investors are seeking objective metrics to assess the issuer's financial stability during periods of market volatility. This indicator reflects the difference between all assets and liabilities, capturing the actual value of net assets. By analyzing the company's balance sheet capital, one can evaluate the actual solvency of the firm. For Personalis, Inc. (PSNL), this is critical when calculating the cash runway for R&D. The indicator's trend demonstrates the business's ability to sustain the development of its cancer diagnostics platform until the Medicare expansion.